Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma.

ABSTRACT:

Background

Temozolomide (TMZ) has been the standard-of-care chemotherapy for glioblastoma (GBM) patients for more than a decade. Despite this long time in use, significant questions remain regarding how best to optimize TMZ therapy for individual patients. Understanding the relationship between TMZ response and factors such as number of adjuvant TMZ cycles, patient age, patient sex, and image-based tumor features, might help predict which GBM patients would benefit most from TMZ, particularly for those whose tumors lack O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation.

Methods and findings

Using a cohort of 90 newly-diagnosed GBM patients treated according to the standard of care, we examined the relationships between several patient and tumor characteristi

SUBMITTER: Massey SC 

PROVIDER: S-EPMC7100932 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature